Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Atopic Dermatitis and Refractory Autoimmune Cholangitis
NCT07678645Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib in atopic dermatitis (AD), primary biliary cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), sponsored by Renji Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)primary biliary cholangitis (PBC)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT07678645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678645.